Glucose variability; does it matter?

Endocrine Reviews

Volumn 31, Issue 2, 2010, Pages 171-182

  Siegelaar, Sarah E ^a   Holleman, Frits ^a   Hoekstra, Joost B L ^a   DeVries, J Hans ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN;

CRITICALLY ILL PATIENT; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; GLUCOSE BLOOD LEVEL; GLUCOSE BLOOD LEVEL VARIABILITY; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; ANIMAL; BLOOD GLUCOSE MONITORING; DIABETES MELLITUS; METABOLISM; METHODOLOGY; PHYSIOLOGY;

ANIMALS; BLOOD GLUCOSE; BLOOD GLUCOSE SELF-MONITORING; DIABETES COMPLICATIONS; DIABETES MELLITUS; HUMANS; HYPOGLYCEMIA; INSULIN; OXIDATIVE STRESS;

EID: 77953628730     PISSN: 0163769X     EISSN: None     Source Type: Journal    
DOI: 10.1210/er.2009-0021     Document Type: Review

References (81)

1. Brownlee M 2001 Biochemistry and molecular cell biology of diabetic complications. Nature 414:813-820
2. Brownlee M 2005 The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54:1615-1625
3. The Diabetes Control and Complications Trial Research Group 1993 The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986
4. The Diabetes Control and Complications Trial Research Group 1995 The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes 44:968-983
5. Brownlee M, Hirsch IB 2006 Glycemic variability: a hemoglobin A1c-independent risk factor for diabetic complications. JAMA 295:1707-1708
6. Lachin JM, Genuth S, Nathan DM, Zinman B, Rutledge BN, for the DCCT/EDIC Research Group 2008 Effect of glycemic exposure on the risk of microvascular complications in the Diabetes Control and Complications Trial-Revisited. Diabetes 57:995-1001
7. da Costa Santos CM, de Mattos Pimenta CA, Nobre MR 2007 The PICO strategy for the research question construction and evidence search. Revista Latino-Americana de Enfermagem 15:508-511
8. Ceriello A, Piconi L, Quagliaro L, Wang Y, Schnabel CA, Ruggles JA, Gloster MA, Maggs DG, Weyer C 2005 Effects of pramlintide on postprandial glucose excursions and measures of oxidative stress in patients with type 1 diabetes. Diabetes Care 28:632-637 (Pubitemid 40315324)
9. Schlichtkrull J, Munck O, Jersild M 1965 the M-value, an index of blood sugar control in diabetics. Acta Med Scand 177:95-102
10. Wójcicki JM 1995 Mathematical descriptions of the glucose control in diabetes therapy. Analysis of the Schlichtkrull "M"-value. Horm Metab Res 27:1-5
11. Service FJ, Molnar GD, Rosevear JW, Ackerman E, Gatewood LC, Taylor WF 1970 Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes 19:644-655
12. McDonnell CM, Donath SM, Vidmar SI, Werther GA, Cameron FJ 2005 A novel approach to continuous glucose analysis utilizing glycemic variation. Diabetes Technol Ther 7:253-263
13. Molnar GD, Taylor WF, Ho MM 1972 Day-to-day variation of continuously monitored glycaemia. Diabetologia 8:342-348
14. Shima K, Tanaka R, Morishita S, Tarui S, Kumahara Y 1977 Studies on the etiology of "brittle diabetes." Relationship between diabetic instability and insulinogenic reserve. Diabetes 26:717-725
15. McCall AL, Cox DJ, Crean J, Gloster M, Kovatchev BP 2006 A novel analytical method for assessing glucose variability: using CGMS in type 1 diabetes mellitus. Diabetes Technol Ther 8:644-653
16. Kovatchev BP, Cox DJ, Gonder-Frederick LA, Clarke W 1997 Symmetrization of the blood glucose measurement scale and its applications. Diabetes Care 20:1655-1658
17. Kovatchev BP, Clarke WL, Breton M, Brayman K, McCall A2005 Quantifying temporal glucose variability in diabetes via continuous glucose monitoring: mathematical methods and clinical application. Diabetes Technol Ther 7:849-862
18. Moberg E, Kollind M, Lins PE, Adamson U 1993 Estimation of blood-glucose variability in patients with insulin-dependent diabetes mellitus. Scand J Clin Lab Invest 53:507-514
19. Wó jcicki JM 1995 "J"-index. A new proposition of the assessment of current glucose control in diabetic patients. Horm Metab Res 27:41-42
20. Ryan EA, Shandro T, Green K, Paty BW, Senior PA, Bigam D, Shapiro AM, Vantyghem MC 2004 Assessment of the severity of hypoglycemia and glycemic lability in type 1 diabetic subjects undergoing islet transplantation. Diabetes 53:955-962
21. Wentholt IM, Kulik W, Michels RP, Hoekstra JB, DeVries JH 2008 Glucose fluctuations and activation of oxidative stress in type 1 diabetes patients. Diabetologia 51:183-190
22. Bugler J, Buell H 2008 Measuring glycemic variability - an estimation of data required based on a 90 day user study. Proc of 27th Workshop of the Artificial Insulin Delivery/Pancreas and Islet Transplantation study group of the European Association for the Study of Diabetes, Innsbruck, Austria, 2008 (Abstract S16)
23. Kishimoto M, Yamasaki Y, Kubota M, Arai K, Morishima T, Kawamori R, Kamada T 1995 1,5-Anhydro-D-glucitol evaluates daily glycemic excursions in well-controlled NIDDM. Diabetes Care 18:1156-1159
24. Buse JB, Freeman JL, Edelman SV, Jovanovic L, McGill JB 2003 Serum 1,5-anhydroglucitol (GlycoMark): a short-term glycemic marker. Diabetes Technol Ther 5:355-363
25. Mehta S, Bucey N, Volkening L, Svoren B, Wood J, Laffel L, Utility of 1,5-anhydroglucitol (1,5-AG) in assessing glycemia among youth and young adults with type 1 diabetes (T1D). Program of the 69th Annual Meeting of The American Diabetes Association, New Orleans, LA, 2009 (Abstract 1802-P)
26. Kuenen J, Borg R, Button E, Nathan D, Zheng H, Kostense P, Heine R, Diamant M, 1,5-Anhydroglucitol concentrations and measures of glucose control and glucose variability in T1DM and T2DM patients. Program of the 69th Annual Meeting of The American Diabetes Association, New Orleans, LA, 2009 (Abstract 882-P)
27. Jay D, Hitomi H, Griendling KK 2006 Oxidative stress and diabetic cardiovascular complications. Free Radic Biol Med 40:183-192
28. Lonn E, Yusuf S, Hoogwerf B, Pogue J, Yi Q, Zinman B, Bosch J, Dagenais G, Mann JF, Gerstein HC 2002 Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: results of the HOPE Study and MICRO-HOPE Substudy. Diabetes Care 25:1919-1927
29. Quagliaro L, Piconi L, Assaloni R, Martinelli L, Motz E, Ceriello A 2003 Intermittent high glucose enhances apoptosis related to oxidative stress in human umbilical vein endothelial cells: the role of protein kinase C and NAD(P)H-oxidase activation. Diabetes 52:2795-2804
30. Piconi L, Quagliaro L, Assaloni R, Da Ros R, Maier A, Zuodar G, Ceriello A 2006 Constant and intermittent high glucose enhances endothelial cell apoptosis through mitochondrial superoxide overproduction. Diabetes Metab Res Rev 22:198-203
31. Takeuchi A, Throckmorton DC, Brogden AP, Yoshizawa N, Rasmussen H, Kashgarian M 1995 Periodic high extracellular glucose enhances production of collagens III and IV by mesangial cells. Am J Physiol 268:F13-F19
32. Mauer SM, Steffes MW, Ellis EN, Sutherland DE, Brown DM, Goetz FC 1984 Structural-functional relationships in diabetic nephropathy. J Clin Invest 74:1143-1155
33. Steffes MW, Bilous RW, Sutherland DE, Mauer SM 1992 Cell and matrix components of the glomerular mesangium in type I diabetes. Diabetes 41:679-684
34. Jones SC, Saunders HJ, Qi W, Pollock CA 1999 Intermittent high glucose enhances cell growth and collagen synthesis in cultured human tubulointerstitial cells. Diabetologia 42:1113-1119
35. Esposito C, Liu ZH, Striker GE, Phillips C, Chen NY, Chen WY, Kopchick JJ, Striker LJ 1996 Inhibition of diabetic nephropathy by a GH antagonist: a molecular analysis. Kidney Int 50:506-514
36. Flyvbjerg A, Orskov H 1990 Kidney tissue insulin-like growth factor I and initial renal growth in diabetic rats: relation to severity of diabetes. Acta Endocrinol (Copenh) 122:374-378
37. Horváth EM, Benko R, Kiss L, Murányi M, Pék T, Fekete K, Bárány T, Somlai A, Csordás A, Szabo C 2009 Rapid 'glycaemic swings' induce nitrosative stress, activate poly-(ADP-ribose) polymerase and impair endothelial function in a rat model of diabetes mellitus. Diabetologia 52:952-961
38. Ceriello A, Esposito K, Piconi L, Ihnat MA, Thorpe JE, Testa R, Boemi M, Giugliano D 2008 Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes 57:1349-1354
39. de Vries JH, Noorda RJ, Voetberg GA, van der Veen EA 1991 Growth hormone release after the sequential use of growth hormone releasing factor and exercise. Horm Metab Res 23:397-398
40. Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, Colette C 2006 Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 295:1681-1687
41. Siegelaar SE, Barwari T, Kulik W, Hoekstra JB, DeVries JH, No relationship between glucose variability and oxidative stress in type 2 diabetes patients. Program of the 45th Annual Meeting of the European Association for the Study of Diabetes, Vienna, 2009 (Abstract 179)
42. Siegelaar SE, Kulik W, van Lenthe H, Mukherjee R, Hoekstra JB, Devries JH 2009 A randomized controlled trial comparing the effect of basal insulin and inhaled mealtime insulin on glucose variability and oxidative stress. Diabetes Obes Metab 11:709-714
43. Kilpatrick ES, Rigby AS, Atkin SL 2006 The effect of glucose variability on the risk of microvascular complications in type 1 diabetes. Diabetes Care 29:1486-1490
44. Kilpatrick ES, Rigby AS, Atkin SL 2007 Variability in the relationship between mean plasma glucose and HbA1c: implications for the assessment of glycemic control. Clin Chem 53:897-901
45. Kilpatrick ES, Rigby AS, Atkin SL 2008 A1c variability and the risk of microvascular complications in type 1 diabetes: data from the DCCT. Diabetes Care 31:2198-2202
46. Bragd J, Adamson U, Bäcklund LB, Lins PE, Moberg E, Oskarsson P 2008 Can glycaemic variability, as calculated from blood glucose self-monitoring, predict the development of complications in type 1 diabetes over a decade? Diabetes Metab 34:612-616
47. Siegelaar SE, Kilpatrick ES, Rigby AS, Atkin SL, Hoekstra JB, Devries JH 2009 Glucose variability does not contribute to the development of peripheral and autonomic neuropathy in type 1 diabetes: data from the DCCT. Diabetologia 52:2229-2232
48. Dossett LA, Cao H, Mowery NT, Dortch MJ, Morris Jr JM, May AK 2008 Blood glucose variability is associated with mortality in the surgical intensive care unit. Am Surg 74:679-685
49. Egi M, Bellomo R, Stachowski E, French CJ, Hart G 2006 Variability of blood glucose concentration and short-term mortality in critically ill patients. Anesthesiology 105:244-252
50. Krinsley JS 2008 Glycemic variability: a strong independent predictor of mortality in critical ill patients. Crit Care Med 36:3008-3013
51. Hirshberg E, Larsen G, Van Duker H 2008 Alterations in glucose homeostasis in the pediatric intensive care unit: hyperglycemia and glucose variability are associated with increased mortality and morbidity. Pediatr Crit Care Med 9:361-366
52. Wintergerst KA, Buckingham B, Gandrud L, Wong BJ, Kache S, Wilson DM 2006 Association of hypoglycemia, hyperglycemia, and glucose variability with morbidity and death in the pediatric intensive care unit. Pediatrics 118:173-179
53. Gimeno-Orna JA, Castro-Alonso FJ, Boned-Juliani B, Lou-Arnal LM 2003 Fasting plasma glucose variability as a risk factor of retinopathy in type 2 diabetic patients. J Diabetes Complications 17:78-81
54. Raz I, Wilson PW, Strojek K, Kowalska I, Bozikov V, Gitt AK, Jermendy G, Campaigne BN, Kerr L, Milicevic Z, Jacober SJ 2009 Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. Diabetes Care 32:381-386
55. van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R 2001 Intensive insulin therapy in critically ill patients. N Engl J Med 345:1359-1367
56. Finfer S, Chittock DR, Su SY, Blair D, Foster D, Dhingra V, Bellomo R, Cook D, Dodek P, Henderson WR, Hébert PC, Heritier S, Heyland DK, McArthur C, McDonald E, Mitchell I, Myburgh JA, Norton R, Potter J, Robinson BG, Ronco JJ; The NICE-SUGAR Study Investigators 2009 Intensive versus conventional glucose control in critically ill patients. N Engl J Med 360:1283-1297
57. The Diabetes Control and Complications Trial Research Group 1997 Hypoglycemia in the Diabetes Control and Complications Trial. Diabetes 46:271-286
58. Gold AE, Frier BM, MacLeod KM, Deary IJ 1997 A structural equation model for predictors of severe hypoglycaemia in patients with insulin-dependent diabetes mellitus. Diabet Med 14:309-315
59. Kovatchev BP, Cox DJ, Farhy LS, Straume M, Gonder-Frederick L, Clarke WL 2000 Episodes of severe hypoglycemia in type 1 diabetes are preceded and followed within 48 hours by measurable disturbances in blood glucose. J Clin Endocrinol Metab 85:4287-4292
60. Jeha GS, Karaviti LP, Anderson B, Smith EO, Donaldson S, McGirk TS, Haymond MW 2005 Insulin pump therapy in preschool children with type 1 diabetes mellitus improves glycemic control and decreases glucose excursions and the risk of hypoglycemia. Diabetes Technol Ther 7:876-884
61. Kudva YC, Basu A, Jenkins GD, Pons GM, Vogelsang DA, Rizza RA, Smith SA, Isley WL 2007 Glycemic variation and hypoglycemia in patients with well-controlled type 1 diabetes on a multiple daily insulin injection program with use of glargine and ultralente as basal insulin. Endocr Pract 13:244-250
62. Saudek CD, Duckworth WC, Giobbie-Hurder A, Henderson WG, Henry RR, Kelley DE, Edelman SV, Zieve FJ, Adler RA, Anderson JW, Anderson RJ, Hamilton BP, Donner TW, Kirkman MS, Morgan NA 1996 Implantable insulin pump vs multiple-dose insulin for non-insulin-dependent diabetes mellitus: a randomized clinical trial. Department of Veterans Affairs Implantable Insulin Pump Study Group. JAMA 276:1322-1327
63. Cox DJ, Kovatchev BP, Julian DM, Gonder-Frederick LA, Polonsky WH, Schlundt DG, Clarke WL 1994 Frequency of severe hypoglycemia in insulin-dependent diabetes mellitus can be predicted from self-monitoring blood glucose data. J Clin Endocrinol Metab 79:1659-1662
64. Murata GH, Hoffman RM, Shah JH, Wendel CS, Duckworth WC 2004 A probabilistic model for predicting hypoglycemia in type 2 diabetes mellitus: the Diabetes Outcomes in Veterans Study (DOVES). Arch Intern Med 164:1445-1450 (Pubitemid 38937856)
65. Kilpatrick ES, Rigby AS, Goode K, Atkin SL 2007 Relating mean blood glucose and glucose variability to the risk of multiple episodes of hypoglycaemia in type 1 diabetes. Diabetologia 50:2553-2561 (Pubitemid 350060641)
66. Van den Berghe G, Wilmer A, Hermans G, Meersseman W, Wouters PJ, Milants I, Van Wijngaerden E, Bobbaers H, Bouillon R 2006 Intensive insulin therapy in the medical ICU. N Engl J Med 354:449-461 (Pubitemid 43200296)
67. Krinsley JS 2004 Effect of an intensive glucose management protocol on the mortality of critically ill adult patients. Mayo Clin Proc 79:992-1000
68. Vriesendorp TM, DeVries JH, van Santen S, Moeniralam HS, de Jonge E, Roos YB, Schultz MJ, Rosendaal FR, Hoekstra JB 2006 Evaluation of short-term consequences of hypoglycemia in the Intensive Care Unit. Crit Care Med 34:2714-2718 (Pubitemid 44610935)
69. Brunkhorst FM, Engel C, Bloos F, Meier-Hellmann A, Ragaller M, Weiler N, Moerer O, Gruendling M, Oppert M, Grond S, Olthoff D, Jaschinski U, John S, Rossaint R, Welte T, Schaefer M, Kern P, Kuhnt E, Kiehntopf M, Hartog C, Natanson C, Loeffler M, Reinhart K, the German Competence Network Sepsis (SepNet) 2008 Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 358:125-139
70. Devos P, Preiser JC, Melot C 2007 Impact of tight glucose control by intensive insulin therapy on ICU mortality and the rate of hypoglycemia: final results of the Glucontrol study. Intensive Care Med 33(Suppl 2):S189
71. The Diabetes Control and Complications Trial Research Group 1996 The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. Diabetes 45:1289-1298
72. Pickup JC, Kidd J, Burmiston S, Yemane N 2006 Determinants of glycaemic control in type 1 diabetes during intensified therapy with multiple daily insulin injections or continuous subcutaneous insulin infusion: importance of blood glucose variability. Diabetes Metab Res Rev 22:232-237 (Pubitemid 43805405)
73. Hartman I 2008 Insulin analogs: impact on treatment success, satisfaction, quality of life, and adherence. Clin Med Res 6:54-67
74. Riddle MC, Rosenstock J, Gerich J 2003 The Treat-to-Target Trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 26:3080-3086 (Pubitemid 37339502)
75. Hermansen K, Davies M, Derezinski T, Martinez Ravn G, Clauson P, Home P, on behalf of the Levemir Treat-to-Target Study Group 2006 A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 29:1269-1274
76. White NH, Chase HP, Arslanian S, Tamborlane WV 2009 Acomparison of glycemic variability associated with insulin glargine and intermediate-acting insulin when used as the basal component of multiple daily injections for adolescents with type 1 diabetes. Diabetes Care 32:387-393
77. Anderson Jr JH, Brunelle RL, Keohane P, Koivisto VA, Trautmann ME, Vignati L, DiMarchi R 1997 Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus. Multicenter Insulin Lispro Study Group. Arch Intern Med 157:1249-1255
78. Kang S, Creagh FM, Peters JR, Brange J, Vølund A, Owens DR 1991 Comparison of subcutaneous soluble human insulin and insulin analogues (AspB9, GluB27; AspB10; AspB28) on meal-related plasma glucose excursions in type I diabetic subjects. Diabetes Care 14:571-577
79. McCall AL, Cox DJ, Brodows R, Crean J, Johns D, Kovatchev B 2009 Reduced daily risk of glycemic variability: comparison of exenatide with insulin glargine. Diabetes Technol Ther 11:339-344
80. Bruttomesso D, Crazzolara D, Maran A, Costa S, Dal Pos M, Girelli A, Lepore G, Aragona M, Iori E, Valentini U, Del Prato S, Tiengo A, Buhr A, Trevisan R, Baritussio A 2008 In type 1 diabetic patients with good glycaemic control, blood glucose variability is lower during continuous subcutaneous insulin infusion than during multiple daily injections with insulin glargine. Diabet Med 25:326-332
81. Alemzadeh R, Palma-Sisto P, Holzum M, Parton E, Kicher J 2007 Continuous subcutaneous insulin infusion attenuated glycemic instability in preschool children with type 1 diabetes mellitus. Diabetes Technol Ther 9:339-347 (Pubitemid 47340083)